Swiss National Bank
VRDN icon

Swiss National Bank’s Viridian Therapeutics VRDN Stock Holding History

Swiss National Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.85M Buy
155,100
+26,500
+21% +$427K ﹤0.01% 1741
2026
Q1 		$2.52M Hold
128,600
– – ﹤0.01% 1741
2025
Q4 		$4M Buy
128,600
+17,900
+16% +$491K ﹤0.01% 1482
2025
Q3 		$2.39M Buy
110,700
+1,800
+2% +$32.5K ﹤0.01% 1764
2025
Q2 		$1.52M Buy
108,900
+1,400
+1% +$19K ﹤0.01% 1942
2025
Q1 		$1.45M Sell
107,500
-5,100
-5% -$86.9K ﹤0.01% 1950
2024
Q4 		$2.16M Buy
112,600
+4,500
+4% +$97.8K ﹤0.01% 1810
2024
Q3 		$2.46M Buy
108,100
+15,500
+17% +$253K ﹤0.01% 1742
2024
Q2 		$1.2M Buy
92,600
+9,700
+12% +$134K ﹤0.01% 2075
2024
Q1 		$1.45M Buy
82,900
+15,700
+23% +$304K ﹤0.01% 2019
2023
Q4 		$1.46M Buy
67,200
+800
+1% +$12.6K ﹤0.01% 2026
2023
Q3 		$1.02M Buy
66,400
+5,700
+9% +$109K ﹤0.01% 2237
2023
Q2 		$1.44M Sell
60,700
-4,400
-7% -$113K ﹤0.01% 2101
2023
Q1 		$1.66M Sell
65,100
-7,100
-10% -$228K ﹤0.01% 1954
2022
Q4 		$2.11M Buy
72,200
+4,800
+7% +$111K ﹤0.01% 1864
2022
Q3 		$1.38M Buy
67,400
+30,700
+84% +$552K ﹤0.01% 2128
2022
Q2 		$425K Buy
+36,700
New +$493K ﹤0.01% 2652

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Swiss National Bank's VRDN Position: Q2 2026 in Review

Swiss National Bank increased its Viridian Therapeutics (VRDN) stake by 21% in Q2 2026, buying an estimated $427K and bringing the position to 155,100 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1741.

Swiss National Bank first reported a position in VRDN in Q2 2022 and has held it in 17 quarters since. The position peaked at $4M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Swiss National Bank held 155,100 shares of Viridian Therapeutics worth $2.85M as of Q2 2026.
  • Swiss National Bank bought 26,500 Viridian Therapeutics shares in Q2 2026, an estimated $427K.
  • Viridian Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1741 holding.
  • Swiss National Bank first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Swiss National Bank's Viridian Therapeutics position peaked at $4M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.